Table 3 Analysis of polymorphisms and lung cancer risk estimates
From: Polymorphism +17 C/G in Matrix Metalloprotease MMP8 decreases lung cancer risk
MMPs | Genotype | Cases n(%) | Controls n(%) | Adjusteda OR [95% CI] | P | P trend |
|---|---|---|---|---|---|---|
MMP1 | 1G/1G | 128 (25.5) | 119 (23.3) | Reference | ||
1G/2G | 248 (49.5) | 259 (50.8) | 0.97 [0.68–1.40] | 0.884 | ||
2G/2G | 125 (25.0) | 132 (25.9) | 1.04 [0.68–1.58] | 0.859 | 0.857 | |
1G/2G + 2G/2G | 373 (74.5) | 391 (76.7) | 0.99 [0.71–1.40] | 0.975 | 0.975 | |
MMP8 | C/C | 392 (79.7) | 358 (75.2) | Reference | ||
C/G + G/G | 100 (20.3) | 118 (24.8) | 0.65 [0.45–0.93] | 0.019 | 0.019 | |
MMP13 | A/A | 248 (49.5) | 267 (52.4) | Reference | ||
A/G | 208 (41.5) | 197 (39.4) | 1.24 [0.91–1.69] | 0.174 | ||
G/G | 45 (9.0) | 42 (8.2) | 1.23 [0.72–2.11] | 0.452 | 0.200 | |
A/G + G/G | 253 (50.5) | 239 (47.6) | 1.24 [0.92–1.66] | 0.155 | 0.155 |